Showing 2717 results
-
Ad-hoc Releases /Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced…
-
Ad-hoc Releases /Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange…
-
Press Release /Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire…
-
Ad-hoc Releases /Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients…
-
Press Release /Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy …
-
Press Release /Acquisition will give Novartis one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system Selective inhibition of the NLRP3…
-
Press Release /Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim Pegfilgrastim is used to reduce the incidence of neutropenia, one…
-
Press Release /China Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is…
-
Press Release /Novartis positioned for sustained growth, including plans to improve Innovative Medicines core margins into mid-30s by 2022 Novartis has a catalyst-rich pipeline with 10 potential blockbuster…
-
Press Release /Basel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of…